A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality

We assessed the effect of stage, grade, and histologic type on cancer-specific mortality after surgery in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials. Important differences exist in the inclusion criteria among the 4 ongoing adjuvant trials. By generating 4 random samples, we have demonstrated that the differences in the inclusion criteria are reflected in the differences in the mortality rates.